“We’re disappointed the Senate was unwilling to compromise on the most far reaching Medicaid drug pricing reform in the country, one that would threaten our stature as the #1 life sciences cluster and harm the development of the next generation of breakthrough therapies. It’s our partnership with academia and government that has supported the level of innovation we see today – innovation that is bringing cures to patients for the first time – and any approach to upend this should be thoughtful and cautious. As the issue moves to conference committee, we will be strongly advocating for inclusion of the House passed language in the final budget.”
– Robert K. Coughlin, President and CEO of MassBio